Systems biology approaches for advancing the discovery of effective drug combinations Rajarshi Guha

Journal of Cheminformatics

Volumn 7, Issue 1, 2015, Pages

  Ryall, Karen A ^a   Tan, Aik Choon ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Korea University   (South Korea)

Author keywords

Cancer; Computational modeling; Drug combinations; Drug discovery; Systems biology

Indexed keywords

EID: 84924288734     PISSN: None     EISSN: 17582946     Source Type: Journal    
DOI: 10.1186/s13321-015-0055-9     Document Type: Article

References (85)

1. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10(6):428-38.
2. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90.
3. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10(2):139-47.
4. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7(8):589-600.
5. Breitkreutz D, Hlatky L, Rietman E, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci U S A. 2012;109(23):9209-12.
6. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer. 2004;4(3):227-35.
7. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000;406(6794):378-82.
8. Lusis AJ, Weiss JN. Cardiovascular networks: systems-based approaches to cardiovascular disease. Circulation. 2010;121(1):157-70.
9. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466-72.
10. Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell. 2012;148(6):1089-98.
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-80.
12. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-43.
13. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80.
14. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077-80.
15. Sun X, Vilar S, Tatonetti NP. High-throughput methods for combinatorial drug discovery. Sci Transl Med. 2013;5(205):205rv1.
16. Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des. 2014;20(1):23-36.
17. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006;2(9):458-66.
18. Chou T, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983;4:450-4.
19. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4(1):71-8.
20. Goldoni M, Johansson C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro. 2007;21(5):759-69.
21. Kreeger PK, Lauffenburger DA. Cancer systems biology: a network modeling perspective. Carcinogenesis. 2010;31(1):2-8.
22. Klipp E, Liebermeister W. Mathematical modeling of intracellular signaling pathways. BMC Neurosci. 2006;7 Suppl 1:S10.
23. Schoeberl B, Eichler-Jonsson C, Gilles ED, Müller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol. 2002;20(4):370-5.
24. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, et al. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol. 2009;5(239):239.
25. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 2010;70(17):6704-14.
26. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009;69(16):6713-20.
27. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009;2(77):ra31.
28. Papin JA, Palsson BO. Topological analysis of mass-balanced signaling networks: a framework to obtain network properties including crosstalk. J Theor Biol. 2004;227(2):283-97.
29. Morris MK, Saez-Rodriguez J, Sorger PK, Lauffenburger DA. Logic-based models for the analysis of cell signaling networks. Biochemistry. 2010;49(15):3216-24.
30. Sahin O, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol. 2009;3:1.
31. Zhang R, Shah MV, Yang J, Shah MV, Yang J, Nyland SB, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008;105(42):16308-13.
32. Aldridge BB, Saez-Rodriguez J, Muhlich JL, Sorger PK, Lauffenburger DA. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput Biol. 2009;5(4):e1000340.
33. Kraeutler MJ, Soltis AR, Saucerman JJ. Modeling cardiac beta-adrenergic signaling with normalized-Hill differential equations: comparison with a biochemical model. BMC Syst Biol. 2010;4(1):157.
34. Saucerman JJ, Brunton LL, Michailova AP, McCulloch AD. Modeling beta-adrenergic control of cardiac myocyte contractility in silico. J Biol Chem. 2003;278(48):47997-8003.
35. Ryall KA, Holland DO, Delaney KA, Kraeutler MJ, Parker AJ, Saucerman JJ. Network reconstruction and systems analysis of cardiac myocyte hypertrophy signaling. J Biol Chem. 2012;287(50):42259-68.
36. Molkentin JD, Dorn GW. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426.
37. Kestler HA, Wawra C, Kracher B, Kühl M. Network modeling of signal transduction: establishing the global view. Bioessays. 2008;30(11-12):1110-25.
38. Alon U. Biological networks: the tinkerer as an engineer. Science. 2003;301(5641):1866-7.
39. Alon U. Network motifs: theory and experimental approaches. Nat Rev Genet. 2007;8(6):450-61.
40. Pelaez N, Carthew RW. Biological robustness and the role of microRNAs: a network perspective. Curr Top Dev Biol. 2012;99:237-55.
41. Yin N, Ma W, Pei J, Ouyang Q, Tang C, Lai L. Synergistic and antagonistic drug combinations depend on network topology. PLoS One. 2014;9(4):e93960.
42. Zhang Y, Smolen P, Baxter DA, Byrne JH. Computational analyses of synergism in small molecular network motifs. PLoS Comput Biol. 2014;10(3):e1003524.
43. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.
44. Ferro A, Giugno R, Pigola G, Pulvirenti A, Skripin D, Bader GD, et al. NetMatch: a Cytoscape plugin for searching biological networks. Bioinformatics. 2007;23(7):910-2.
45. Ryall KA, Bezzerides VJ, Rosenzweig A, Saucerman JJ. Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J Mol Cell Cardiol. 2014;72:74-84.
46. Yedidia JS, Freeman WT, Weiss Y. Understanding belief propagation and its generalizations. In: Exploring Artificial Intelligence in the New Millennium. 2002. p. 239-69.
47. Molinelli EJ, Korkut A, Wang W, Miller ML, Gauthier NP, Jing X, et al. Perturbation biology: inferring signaling networks in cellular systems. PLoS Comput Biol. 2013;9(12):e1003290.
48. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Causal protein-signaling networks derived from multiparameter single-cell data. Science. 2005;308(5721):523-9.
49. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35.
50. Qu XA, Rajpal DK. Applications of connectivity map in drug discovery and development. Drug Discov Today. 2012;17(23-24):1289-98.
51. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321-30.
52. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10(4):331-42.
53. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10.
54. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan A, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Trans Med. 2011;3(96):96ra77.
55. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther. 2012;11(5):1214-5.
56. Kim J, Yoo M, Kang J, Tan AC. K-Map: connecting kinases with therapeutics for drug repurposing and development. Hum Genomics. 2013;7(1):20.
57. Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, et al. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 2014;30(17):2393-8.
58. Pal R, Berlow N. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs. Pac Symp Biocomput. 2012;351-62.
59. Berlow N, Davis LE, Cantor EL, Séguin B, Keller C, Pal R. A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC Bioinformatics. 2013;14(1):239.
60. Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, et al. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol. 2013;9(9):e1003226.
61. Gujral TS, Peshkin L, Kirschner MW. Exploiting polypharmacology for drug target deconvolution. Proc Natl Acad Sci U S A. 2014;111(13):5048-53.
62. Huang L, Li F, Sheng J, Xia X, Ma J, Zhan M, et al. DrugComboRanker: drug combination discovery based on target network analysis. Bioinformatics. 2014;30(12):i228-36.
63. Pang K, Wan Y, Choi WT, Donehower LA, Sun J, Pant D, et al. Combinatorial therapy discovery using mixed integer linear programming. Bioinformatics. 2014;30(10):1456-63.
64. Liu Y, Hu B, Fu C, Chen X. DCDB: drug combination database. Bioinformatics. 2010;26(4):587-8.
65. Xu KJ, Song J, Zhao XM. The drug cocktail network. BMC Syst Biol. 2012;6 Suppl 1:S5.
66. Cheng F, Zhao Z. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am Med Inf Assoc. 2014;21(e2):e278-86.
67. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007;6(7):556-68.
68. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402.
69. Prahallad A, Sun C, Huang S, Nicolantonio FD, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-3.
70. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2012;110(2):E170-9.
71. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013;19(15):4149-62.
72. Tan X, Hu L, Luquette LJ, Gao G, Liu Y, Qu H, et al. Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol. 2012;30(11):1125-30.
73. Roller D, Axelrod M, Capaldo B, Jensen K, Mackey A, Michael J. Synthetic lethal screening with small molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther. 2012;11(11):2505-15.
74. Matthews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349-54.
75. Holbeck S, Collins JM, Doroshow JH. NCI-60 combination screening matrix of approved anticancer drugs. Eur J Cancer. 2012;48(Suppl:6):11.
76. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323-34.
77. Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A. 2014;111(29):10773-8.
78. Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014;4(2):166-74.
79. Pe'er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell. 2011;144(6):864-73.
80. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10(4):241-53.
81. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338-50.
82. Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst. 2013;105(19):1441-56.
83. Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012;4(126):126ps7.
84. Sorger PK, Allerheiligen SRB. Quantitative and systems pharmacology in the post-genomic Era: New approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP workshop group. 2011. p. 0-47.
85. Feala JD, Cortes J, Duxbury PM, Piermarocchi C, McCulloch AD, Paternostro G. Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip Rev Syst Biol Med. 2010;2(2):181-93.